|Bid||0.00 x 800|
|Ask||0.00 x 1400|
|Day's Range||26.63 - 27.11|
|52 Week Range||10.94 - 27.79|
|PE Ratio (TTM)||3.93|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.33|
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the Trump administration released details on the latest round of China tariffs, to which China has responded in kind. In other news, the June Empire State Manufacturing Survey beat Wall Street expectations on nearly every front. Here's the performance of select trending stocks as of 10:00 am ET: GERN(HB) Geron Corp 4.36% TXMD(HB) TherapeuticsMD Inc 3.56% NXPI NXP Semiconductors N.V. 3.09% TVIX(HB) VS 2X VIX Short Term 2.97% SHLD(HB) Sears Hldg Corp 2.79% AKER(HB,H,0) Akers Biosciences Inc 2.23% HMNY(HB) Helios and Matheson Analytics 1.80% UVXY(HB) ProShs Ultra VIX Short-Term 1.64% MO Altria Grp 1.62% VXX iPath S&P 500 VIX Short-Term 1.42% DKS Dick's Sporting Goods 1.42% KORS Michael Kors Hldg, Ltd. 1.37% NKE Nike Inc Cl B 1.08% CGC(HB) Canopy Growth 0.95% COST Costco Wholesale Corp 0.95% PG Procter & Gamble Cc 0.99% TSLA(HB) Tesla Inc 0.92% SNAP(HB) Snap Inc 0.97% MDGL Madrigal Pharma Inc 1.11% AAOI(HB,0) Applied Optoelectronice Inc 0.82% SIRI(HB) Sirius XM Hldgs Inc 0.81% HD Home Depot Inc 0.76% TWTR Twitter Inc 0.53% TRXC(HB) TransEnterix Inc 0.69% AVGO(HB) Broadcom Inc 0.56% ABBV AbbVie Inc 0.50% KO Coca-Cola Co 0.46% VKTX(HB) Viking Therapeutics Inc 0.09% VRX Valeant Pharma Intl Inc 0.32% AMD Advanced Micro Devices Inc 0.19% CELG Celgene Corp 0.18% WFC Wells Fargo 0.10% CRSP(HB) CRISPR Therapeutics AG 0.08% JCP(HB) Penney (J.C.) 0.00% SQ Square Inc 0.00% V Visa Inc -0.07% PFE Pfizer Inc -0.07% DIS Disney (Walt) Co -0.01% JD JD.com Inc -0.14% WMT Wal-Mart Stores -0.06% TEVA Teva Pharm Indus ADR -0.04% JNJ Johnson & Johnson -0.17% VZ Verizon Communications -0.22% T AT&T Inc -0.28% GOOGL Alphabet Inc Cl A -0.28% NVDA Nvidia Corp -0.32% CRM salesforce.com Inc -0.33% F Ford Motor -0.34% AMAT Applied Materials -0.27% IBM Intl Business Machines Corp -0.41% NOK Nokia Corp ADS -0.41% GOOG Alphabet Inc Cl C Cap Stock -0.43% QQQ(HB) Invesco QQQ Trust Series 1 -0.46% BRK.B(HB) Berkshire Hathaway'B' -0.50% KMI Kinder Morgan Inc -0.50% CVX Chevron Corporation -0.55% ROKU Roku Inc Cl A -0.36% QCOM Qualcomm Inc -0.59% MSFT Microsoft Corp -0.59% C Citigrp Inc -0.70% SBUX Starbucks Corp -0.68% SPY SPDR S&P 500 ETF -0.79% GM General Motors Co -0.76% GS Goldman Sachs Grp -0.92% MU Micron Tech -0.88% NVCN(HB,F) Neovasc Inc -0.91% JPM JPMorgan Chase & Co -0.99% XOM Exxon Mobil -1.01% BIDU Baidu Inc -0.96% PLUG(HB) Plug Power, Inc. -1.26% PYPL PayPal Hldgs Inc -1.05% INTC Intel Corp -1.16% HPQ HP Inc -1.18% BOX(0) Box, Inc -1.24% GILD Gilead Sciences -1.19% BAC Bank of America Corporation -1.47% BABA Alibaba Group Holding Ltd -1.41% MOMO Momo Inc ADS -1.47% GE General Electric Co -1.52% DB(HB) Deutsche Bank Ag Ord -1.52% BA(HB) Boeing Co -1.63% CAT Caterpillar Inc -1.85% BP BP P.L.C. ADS -1.87% TCEHY(HB) Tencent Hldgs Ltd -1.83% CSCO Cisco Systems -1.87% PBR Petroleo Brasileiro S.A. ADS -2.15% IQ(HB) IQIYI Inc ADS -2.25% CHK Chesapeake Energy Corp -2.68% CLF Cleveland-Cliffs Inc -2.95% AKS AK Steel Hldg -3.33% JNUG(HB) DX Jr Gold Miners Bull 3x -3.90% X U.S. Steel Corporation -4.07% OLED(3) Universal Display Corp -4.26% 0005.HK ACB.TO ^RUT CADUSD=X GC=F BBD-B.TO YM=F
Now, Sprout Pharmaceuticals will make a second attempt to sell the drug but using a different method. Most importantly, Sprout will sell the drug for just $400, a 50% markdown from Valeant’s selling price. Both companies have an interest in getting patients prescribed on Addyi.
The U.S. government is shifting its focus from accusing drug companies of overcharging to encouraging the marketplace to operate more competitively. On May 31, FDA Commissioner Scott Gottlieb, announced a draft guidance that will limit drug companies in delaying generics to market. Previously, generics needed to negotiate with branded firms.
Now Available at Major U.S. Retailers LAVAL, Quebec , June 14, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International ...
It’s take two for Sprout Pharmaceuticals and Addyi, the only drug approved by the U.S. Food and Drug Administration to treat low sexual desire disorder (HSDD) in women.
This past January, when Cindy Eckert got back the keys to her old office in Raleigh, N.C., she walked into a time capsule. It was the first time Eckert had entered the office since she sold—and was then pushed out of—her company, Sprout Pharmaceuticals Inc. She and her then-husband started the company to bring to market the first drug to enhance female sexual desire. Since that moment, the story of Addyi, the pink pill, has been frozen in time.
The covenant quality of North American bonds sharply worsened in May, driven by significantly-weakened private-equity sponsored bonds, Moody's Investors Service says in its latest monthly report. Moody's ...
LAVAL, Quebec, June 12, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), today announced the introduction of Ocuvite® Blue Light eye vitamins, a nutritional supplement formulated with lutein and zeaxanthin, the two carotenoid pigments naturally found in the eye. This formulation of eye nutrients includes high levels of lutein and helps protect eyes from the blue light that reaches the macula, which is responsible for our central vision. "With the increasing number of hours Americans are spending on digital devices, there is a growing need for a product that helps our eyes filter the blue light that is emitted from these devices," said Joseph Gordon, president, Consumer Healthcare and Vision Care, Bausch + Lomb.
As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a non-GAAP EPS of $0.88 on revenues of ~$2.0 billion during the first quarter. Valeant had a 5.4% decline in its year-over-year revenues during the first quarter due to a 9% decrease in operating revenues. The decrease was partially offset by the favorable impact of foreign exchange—compared to revenues of ~$2.1 billion during the first quarter of 2017.
NEW YORK, NY / ACCESSWIRE / June 11, 2018 / U.S. markets finished higher and logged strongest week in months as investors shrug off tensions between U.S. and its allies. The Dow Jones Industrial Average ...
As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a 9% decrease in its operating revenues to ~$2.0 billion during the first quarter—compared to revenues of ~$2.1 billion during the first quarter of 2017. On June 1, Valeant entered into a fourth amended and restated credit and guarantee agreement to refinance its secured revolving and term loan credit facilities. The company also closed the offering of 8.500% senior notes due in 2027 by a wholly owned indirect subsidiary.
Entwistle & Cappucci LLP (“Entwistle & Cappucci”) today announced that it has filed a securities class action lawsuit on behalf of persons or entities that purchased call options and/or sold put options on Valeant Pharmaceuticals International, Inc. (VRX) (“Valeant” or the “Company”) common stock during the period January 4, 2013 through August 11, 2016, inclusive (the “Class Period”), and who were damaged thereby (the “Class”). The case was filed in the United States District Court for the District of New Jersey, Case No. 3:18-cv-10246, against Valeant and related defendants (collectively, “Defendants”). The class action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Valeant Pharmaceuticals (VRX) reported a GAAP net loss of ~$2.7 billion during the first quarter—compared to the GAAP net income of ~$628 million during the first quarter of 2017. Also, the GAAP EPS was negative at -$7.68. The company reported a loss during the first quarter—compared to the GAAP EPS of $1.79 during the first quarter of 2017.
Valeant Pharmaceutical’s (VRX) revenues decreased ~5.4% to ~$2.0 billion during the first quarter—compared to revenues of ~$2.1 billion during the first quarter of 2017. Valeant met Wall Street analysts’ revenue estimates and reported revenues of ~$1.995 billion—compared to estimates of ~$1.944 billion during the first quarter. Valeant reported organic growth of 2% in total revenues during the first quarter.
After June, you won’t have Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to kick around anymore. The Canada-based drug company is changing its name on Jul. 1 to Bausch Health Corp. That, along with the new ticker symbol (BHC), is supposed to put the company’s past behind it once and for all, leading to growth and profit for investors. Analysts are buying it. CEO Joseph Papa has fulfilled his promises to stop the rot, fix the balance sheet, and get the drug pipeline going again.
Valeant Pharmaceuticals (VRX) is one of the pharmaceutical companies that’s focused on developing and commercializing prescription pharmaceuticals, generic pharmaceuticals, over-the-counter products, and eye care products. Wall Street analysts expect revenues of ~$2.1 billion during the second quarter.
Valeant (VRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending market topics from the floor of the New York Stock Exchange.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer thinks Barclay's $29 price target on Valeant Pharmaceuticals is "very right."
Jim Cramer says he now sees value in Valeant Pharmaceuticals after its chairman and CEO, Joe Papa, guided the company through its recent challenges. Cramer mentions a positive note by Barclays analyst Douglas Tsao on Wednesday regarding Valeant Pharmaceuticals. CNBC's Jim Cramer said Wednesday that he now sees value in Valeant Pharmaceuticals VRX-CA after its chairman and CEO, Joe Papa, guided the company through its recent challenges.
Barclays' Douglas Tsao takes a look at the specialty-pharmaceutical sector on Wednesday, upgrading Valeant Pharmaceuticals International (VRX) and downgrading Perrigo (PRGO). Taso boosted his rating on Valeant to Overweight, writing that his bullishness comes from his belief that the company's hit an inflection point, and the existing business has stabilized, leaving Valeant positioned to benefit from growth via new product launches. By contrast, he lowered is rating on Perrigo to Equal Weight, writing that the company's inability to win approval for its generic version of its inhaler ProAir "reduces near-term earnings momentum." Taso writes that management previously hoped for the treatment to continue nine cents to 2018 EPS, and even more in 2019, which now looks overly optimistic.